FORM 3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			1	Section 30(h						
1. Name and Addres <u>Goldwasser N</u>	i.	2. Date of Event Requir Statement (Month/Day/ 10/19/2022		3. Issuer Name and Ticker or Trading Symbol Prime Medicine, Inc. [PRME]						
(Last) (First) (Middle) C/O PRIME MEDICINE, INC. 21 ERIE STREET					4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP, Strategy & Corporate Ops.			5. If Amendment, Date of Original Filed (Month/Day/Year)     6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person		
(Street) CAMBRIDGE MA 02139			_		Svr, Strategy & Corpo	nate Ops.		Form filed by More than One Reporting Pe		
(City)	(State)	(Zip)								
			Table I - I	Non-Deri	vative Securities Beneficially Ow	ned				
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Dwned (Instr. 4)	3. Ownership Form: 4. Direct (D) or Indirect (I) (Instr. 5)		. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock					176,917	D				
					tive Securities Beneficially Owne rrants, options, convertible secu					
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable a Expiration Date (Month/Day/Year)			ate	Security (Instr. 4)		Conversion or Exercise	5. Ownership Form: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficia Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	(Instr. 5)		
Stock Option (right to buy)			(1)	10/27/2031	Common Stock	48,250	3.67	D		

Explanation of Responses:

1. 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 27, 2021, subject to the Reporting Person's continued service on each such vesting date. Remarks:

Exhibit 24 - Power of Attorney

/s/ Carman Alenson attorney-in-fact \*\* Signature of Reporting Person Date

<u>10/19/2022</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78f(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Keith Gottesdiener, Carman Alenson and Karen Brown of Prime Medicine, Inc., a Delaware (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, from time to t (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any sucl (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of 1 The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and t1 This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of October 19, 2022.

## /s/ Meredith Goldwasser

Signature

#### Meredith Goldwasser

Print Name